La vendita allo scoperto per NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd. dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd.. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd. (OTC:NKYSF) Azioni, Report sulle vendite allo scoperto

NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd.

Truist Securities analyst Michael Ciarmoli maintains AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) with a Buy and lowers the price target from $10 to $8.

News

Price Target

Analyst Ratings

ASLE

Truist Securities Maintains Buy on AerSale, Lowers Price Target to $8

P&G CFO Says Co Saw Stock-Up Situation As A Quick Run Up Due To The Port Strike Which Didn't Really Have A Material Impact On This Quarter; The Stock-Up Situation Due To Port Strikes Was Very Short-Lived

Citigroup analyst Scott Gruber downgrades Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) from Buy to Neutral and lowers the price target from $25 to $19.

Downgrades

LBRT

Citigroup Downgrades Liberty Energy to Neutral, Lowers Price Target to $19

American Express CFO Says Impact Of Fed Rate Cuts On Our Net Interest Income Is Actually Quite Small

Ladenburg Thalmann analyst Glenn Mattson initiates coverage on Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) with a Buy rating and announces Price Target of $16.5.

Initiation

NEON

Ladenburg Thalmann Initiates Coverage On Neonode with Buy Rating, Announces Price Target of $16.5

On Thursday,&nbsp;Aura Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41390774/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-" rel="noreferrer noopener">bladder cancer (NMIBC)</a>.
To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40837403/aura-biosciences-touts-promising-data-from-eye-cancer-candidate" rel="noreferrer noopener">Aura Biosciences Touts Promising Data From Eye Cancer Candidate</a>.
The secondary endpoints are to evaluate biological activity and immune-mediated changes in the tumor microenvironment (TME).
In patients receiving bel-sar with light activation (n=8), 4 out of 5 patients with low-grade disease demonstrated a clinically complete response with no tumor cells remaining on histopathological evaluation.
Two out of 3 patients with high-grade disease demonstrated visual tumor shrinkage observed on cystoscopy.
The data in these eight patients receiving bel-sar with light activation showed clinical activity detectable as soon as seven days after a single low dose of bel-sar with light activation.
&#8220;A potentially differentiating aspect of this novel treatment is the rapid tumor response accompanied by an immune-oncology effect such as a marked CD8+ T-cell infiltration observed in just a matter of days with a single low dose. We believe this could have the potential to translate into a durable response. In parallel with expanding the ongoing Phase 1 trial, we are preparing for a Phase 2 trial to further evaluate bel-sar&#8217;s clinical activity and durability of response,&#8221; said Sabine Brookman-May, Senior Vice President, Therapeutic Area Head Urologic Oncology of Aura Biosciences.
In the safety analysis as of Sept. 9, data cut-off date (n=12), bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported.
No serious adverse events have been reported.
Price Action: AURA stock traded 18.85% higher at $12.23 during after-hours trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" target="_blank" rel="noreferrer noopener">Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

AURA

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

<ul>
<li>NVDA</li>
<li>NFLX</li>
<li>TSLA</li>
<li>AAPL</li>
<li>WAY</li>
<li>QQQ</li>
<li>MADE</li>
<li>AI</li>
<li>TSM</li>
<li>GOLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

MADE

NFLX

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of October 18, 2024 (Via Swaggy Stocks)

Joe Rogan recently discussed how people are starting to think differently about capitalism, money and yes, one of his favorite topics – <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a>. In a <a href="https://www.youtube.com/watch?v=ws2ZsG3NNQc">conversation</a> with musician Jelly Roll, Rogan talked about how things are changing in both the entertainment world and the way people feel about capitalism. He said both areas have seen a lot of changes recently.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> 7-9% target yield with monthly dividends would you invest in it?</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
&#8220;Everybody&#8217;s worried about like this collapse of society because people, they give up on
capitalism. They tune in and drop out,&#8221; he started before saying, &#8220;I don&#8217;t think we should be worried about that. I don&#8217;t think that&#8217;s real.&#8221;&nbsp;
He believes that while some people might want to &#8220;drop out&#8221; of the system, it won't affect most people. He thinks those people are just the type who would probably reject the system no matter what.
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Rogan added that some people will always want to drop out and avoid responsibility. If given an excuse, they will take it, but that's just their personality. He believes this type of person doesn't represent most people and that most people could benefit from the system, especially if they don&#8217;t have major mental health issues.
Although Rogan and Roll talked a lot about psychedelics in this episode, what&#8217;s more interesting is what Rogan discussed in a different episode with Michael Malice. In it, they talked about how psychedelics, like <a href="https://www.benzinga.com/markets/cannabis/24/09/40858292/magic-mushrooms-boosted-humanitys-evolutionary-success-new-study-says-did-psilocybin-make-early-">magic mushrooms</a>, could change the corporate world.&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Yes, Rogan said that if these drugs became legal and business leaders started using them, <a href="https://www.benzinga.com/personal-finance/24/08/40133472/joe-rogan-tells-ceos-life-is-short-youre-wasting-all-your-time-trying-to-squeeze-as-much-money-a">they might start to care more about people</a> and less about making as much money as possible. He said this is a &#8220;psychedelic capitalist perspective,&#8221; in which maximizing profits is equated with doing the right thing and not hurting anyone.
On a similar note, Rogan laughed and added that this might even make it &#8220;much harder to get a good burger&#8221; since fast-food workers might quit their jobs after taking psychedelics and seeing things differently.
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
In 2017, he compared this way of thinking to former President Donald Trump, saying Trump is like someone who believes &#8220;greed is good.&#8221; Rogan warned that this thinking is &#8220;a dangerous ideology&#8221; for society, saying, "I mean, our president is essentially the greed-is-good guy. I mean, that is who he is that's what he's done. He's pursued wealth at all cost."
Rogan&#8217;s ideas aren't without controversy. Even though he often talks <a href="https://www.benzinga.com/personal-finance/24/09/40909092/joe-rogan-says-education-addiction-recovery-and-homelessness-should-be-funded-more-its-a-good-id">against corporate greed</a>, he is friends with some of the world&#8217;s richest and most powerful people. He called <a href="https://www.benzinga.com/news/24/05/38978082/joe-rogan-says-elon-musk-is-his-favorite-billionaire-i-will-buy-teslas-as-long-as-they-sell-them-jus">Elon Musk his &#8220;favorite billionaire&#8221;</a> and said he&#8217;d keep buying Tesla cars to support him. Some have referred to Rogan as hypocritical because of this, particularly considering that his podcast is among the most popular.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Startups

'I Don't Think We Should Be Worried About That,' Says Joe Rogan About People Giving Up On Capitalism – 'I Don't Think That's Real'

Lake Street analyst Jacob Stephan downgrades Zuora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZUO#NYSE">ZUO</a>) from Buy to Hold and announces $10 price target.

Lake Street Downgrades Zuora to Hold, Announces $10 Price Target

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $300 to $310.

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $310

Lake Street analyst Ben Klieve downgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Buy to Hold and announces $75 price target.

MGPI

Lake Street Downgrades MGP Ingredients to Hold, Announces $75 Price Target

WIIM

Procter & Gamble shares are trading lower following a Q1 revenue miss.

Morgan Stanley analyst Michael Cyprys maintains T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Equal-Weight and raises the price target from $125 to $127.

TROW

Morgan Stanley Maintains Equal-Weight on T. Rowe Price Gr, Raises Price Target to $127

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 90 points on Friday.
Shares of CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) fell sharply in today's pre-market trading after the company cut its <a href="https://www.benzinga.com/quote/CVS">third-quarter outlook.</a>
CVS Health appointed longtime executive David Joyner as its new president and CEO, replacing Karen Lynch amid the company's ongoing financial struggles. The company warned that its upcoming third-quarter earnings, set for release on November 6, will miss Wall Street projections.
CVS Health shares dipped 11.6% to $56.29 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>MGP Ingredients, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) shares dipped 16.6% to $68.06 after the company issued soft preliminary guidance and lowered its 2024 financial outlook.</li>
<li>Coherent Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NASDAQ">COHR</a>) shares fell 4.6% to $97.39 in pre-market trading.</li>
<li>Zeta Global Holdings Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares fell 4.5% to $28.66 in pre-market trading. Zeta is expected to release its third quarter 2024 financial results after the closing bell on Monday, Nov. 11.</li>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 4.3% to $2.03 in pre-market trading after declining around 5% on Thursday.</li>
<li>GrafTech International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NASDAQ">EAF</a>) shares fell 4.1% to $1.62 in pre-market trading.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares fell 3.8% to $2.55 in pre-market trading. HC Wainwright &amp; Co. analyst Amit Dayal reiterated Gevo with a Buy and maintained a $14 price target.</li>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) shares fell 3.6% to $275.50 in pre-market trading following third-quarter results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) shares fell 3.5% to $29.00 in pre-market trading. Fresh Del Monte Produce will issue a press release on its third quarter financial results prior to market opening on Thursday, Oct. 31.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41390636/top-2-real-estate-stocks-that-may-fall-off-a-cliff-in-q4">Top 2 Real Estate Stocks That May Fall Off A Cliff In Q4</a></li>
</ul>

Pre-Market Outlook

Markets

COHR

GEVO

ZETA

ZJYL

CVS Health Cuts Outlook, Joins American Express And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Morgan Stanley analyst Michael Cyprys maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Equal-Weight and raises the price target from $16 to $17.

Morgan Stanley Maintains Equal-Weight on Invesco, Raises Price Target to $17

Amid skepticism surrounding Tesla Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) &#8220;Optimus&#8221; robots, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) executive Rev Lebaredian has stepped in to defend the technology. 
What Happened: Reports from the &#8220;We Robot&#8221; event indicated that the humanoid robots were operated by engineers, sparking criticism over the authenticity of their capabilities. Despite this, Lebaredian emphasized the complexity and technological prowess involved in controlling these robots, Business Insider <a href="https://www.businessinsider.com/nvidia-praises-tesla-ai-optimus-robot-remote-control-concerns-2024-10">reported</a> on Friday.
&#8220;Mapping your controls to the robot acting in the real world and interacting with others around — that&#8217;s a huge, huge advancement, and it&#8217;s not something that should be downplayed,&#8221; he said.
Tesla&#8217;s &#8220;Optimus&#8221; robots recently faced scrutiny after it was revealed that <a href="https://www.benzinga.com/news/24/10/41354482/tesla-engineer-admits-optimus-robots-were-human-assisted-to-some-extent-at-robotaxi-unveiling-event">they were remotely controlled </a>by engineers during a demonstration. At the event, the robots showcased their abilities by performing tasks such as dancing and pouring drinks. Some critics labeled the demonstration as misleading. 
Lebaredian, who has been with Nvidia for 23 years, acknowledged that skepticism is a common reaction to new technology. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41348730/elon-musks-tesla-waving-goodbye-to-bitcoin-760m-sent-to-unknown-wallets?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Tesla Waving Goodbye To Bitcoin? $760M Sent To Unknown Wallets</a>
Why It Matters: Both Elon Musk and Jensen Huang, Nvidia&#8217;s CEO, are heavily invested in the <a href="https://www.benzinga.com/news/24/03/37862375/jensen-huang-reveals-why-nvidia-is-betting-big-on-humanoid-robot-and-embodied-ai">development of humanoid robots</a>, viewing them as a crucial element of future technological progress. Musk has touted &#8220;Optimus&#8221; as a major product, while Nvidia is <a href="https://www.benzinga.com/news/24/07/40038962/nvidia-drives-value-with-ai-and-robotics-software-services">committed to advancing robotics</a> as a key market.
The collaboration between Tesla and Nvidia has been pivotal in advancing AI technology. In June, Tesla&#8217;s Giga Texas expansion was revealed to<a href="https://www.benzinga.com/news/24/06/39404789/drone-footage-reveals-tesla-giga-texas-expansion-work-to-house-50-000-nvidia-gpus-ceo-elon-musk-says"> include 50,000 Nvidia GPUs</a>, underscoring the importance of Nvidia&#8217;s technology in Tesla&#8217;s AI efforts. This expansion aims to enhance Tesla&#8217;s AI capabilities, as seen in their autonomous driving software. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41349340/elon-musk-announces-tesla-semi-will-be-available-worldwide-amid-growing-skepticism-over-500-mile?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Announces Tesla Semi &#8216;Will Be Available Worldwide&#8217; Amid Growing Skepticism Over 500-Mile Range And Autonomous Features</a></li>
</ul>
Photo courtesy: Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Tech

Nvidia Executive Defends Tesla's 'Optimus' Robots Amid Criticism: 'That's A Huge Advancement...Not Something That Should Be Downplayed'

Morgan Stanley analyst Michael Cyprys maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Underweight and raises the price target from $208 to $217.

VRTS

Morgan Stanley Maintains Underweight on Virtus Inv, Raises Price Target to $217

RBC Capital analyst Jon Arfstrom maintains Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) with a Sector Perform and raises the price target from $148 to $161.

RBC Capital Maintains Sector Perform on Discover Finl, Raises Price Target to $161

Schlumberger N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) shares are trading lower after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399037/slb-announces-third-quarter-2024-results" rel="noreferrer noopener">mixed third-quarter results</a>. Revenue grew 10.2% year over year to $9.159 billion, missing the consensus of $9.25 billion.
SLB stated that revenue increased in the Middle East, Asia, and offshore North America but was counterbalanced by a decline in Latin America, with Europe and Africa remaining stable.
Adjusted EPS increased 14% to 89 cents, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">above the consensus of 88 cents.</a>
Revenue by Division: Digital &amp; Integration $1.09 billion (+11% Y/Y); Reservoir Performance $1.823 billion (+9% Y/Y); Well Construction $3.312 billion (-3% Y/Y), and Production Systems $3.103 billion (+31% Y/Y).
International revenue grew 12% year over year, with growth of 16% in the Middle East &amp; Asia and 16% in Europe &amp; Africa. North American market revenue rose 3%.
Related: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41397102/slb-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-anal" rel="noreferrer noopener">SLB Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
&#8220;This performance was achieved despite an environment where short-cycle activity growth softened, and some international producers exercised cautious spending triggered by lower oil prices and ample global supply, while land activity in the U.S. remained subdued,&#8221; commented SLB CEO Olivier Le Peuch.
Adjusted EBITDA was $2.34 billion for the quarter, an increase of 12.6% Y/Y, and margin expanded 54 bps to 25.6%. The pretax segment operating margin expanded by 51 bps for the quarter to 20.8%.
Operating cash flow for the nine months totaled $4.212 billion compared to $3.615 billion a year ago, and free cash flow was $2.36 billion.
For the quarter, cash flow from operations was $2.45 billion, and free cash flow was $1.81 billion.
Dividend: SLB declared a quarterly cash dividend of $0.275 per share, payable on January 9, 2025, to stockholders of record on December 4, 2024.
Cash and short-term investments stood at $4.462 billion as of September 30. SLB repurchased 11.3 million for $501 million during the quarter.
Additionally, SLB announced a definitive agreement to sell its interests in the Palliser Block located in Alberta, Canada. <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41393134/slb-announces-definitive-agreement-to-sell-its-interests-in-palliser-block" rel="noreferrer noopener">Deal terms were not disclosed.</a>
Price Action: SLB shares are trading lower by 1.41% at $43.37 premarket at the last check Friday.
Image via Shutterstock

Earnings

Equities

Dividends

Schlumberger Q3 Earnings: Mixed Results As Middle East Shines And Latin America Falters

Morgan Stanley analyst Michael Cyprys maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and lowers the price target from $21 to $19.

Comments

NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd.

Vendite allo scoperto

NAKAYAMA STEEL WORKS LTD by Nakayama Steel Works Ltd. (OTC:NKYSF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO